C12N 2730/10143
Viral genome or elements thereof as genetic vector
Official title: viral genome or elements thereof as genetic vector
C12N2730/10143 (Viral genome or elements thereof as genetic vector) appears on 23 US grants and 48 published applications in this corpus.
Search patents in C12N- Granted patents
- 23
- Published applications
- 48
- Assignees
- 30
- Inventors
- 93
- Latest grant
- 24 Mar 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 0 |
| 2003 | 1 | 2 |
| 2004 | 0 | 1 |
| 2005 | 0 | 3 |
| 2006 | 2 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 8 |
| 2013 | 1 | 2 |
| 2014 | 3 | 4 |
| 2015 | 0 | 2 |
| 2016 | 2 | 4 |
| 2017 | 1 | 3 |
| 2018 | 3 | 0 |
| 2019 | 1 | 2 |
| 2020 | 2 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 4 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 3 | 0 |
| 2026 | 1 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Composition for regulating production of interfering ribonucleic acid24 Mar 2026US 12,584,129 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid23 Dec 2025US 12,503,697 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid2 Dec 2025US 12,486,506 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid25 Nov 2025US 12,480,121 B1Wyvern Pharmaceuticals Inc.
- Recombinant HBV reporter system14 Feb 2023US 11,578,321 B2Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Viral open reading frames, uses thereof, and methods of detecting the same30 Jul 2026US 2026/0218238 A1President and Fellows of Harvard College
- Compositions and methods for treating genetic disorders9 Jul 2026US 2026/0191908 A1
- Composition for regulating production of interfering ribonucleic acid26 Mar 2026US 2026/0085312 A1Wyvern Pharmaceuticals Inc.
- Genetic therapy for glaucoma and optic neuropathies14 Mar 2024US 2024/0082428 A1The Board of Trustees of the Leland Stanford Junior University
- High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier20 Oct 2022US 2022/0332770 A1
Most cited
By later US patents
- Recombinant hepatitis virus vectors115US 5,981,274 A1999
- Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof45US 7,842,489 B2Cellectis · 2010
- Hepatitis B virus vectors for gene therapy7US 7,001,760 B22006
- Particles for gene therapy6US 7,018,826 B1Island Pharmaceuticals, Ltd. · 2006
- Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof5US 8,530,214 B2Cellectis · 2013